Literature DB >> 17235040

Targeting HER2 in prostate cancer: where to next?

David B Solit, Neal Rosen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17235040     DOI： 10.1200/JCO.2006.08.8187

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  12 in total

1.  Decline in arylsulfatase B expression increases EGFR expression by inhibiting the protein-tyrosine phosphatase SHP2 and activating JNK in prostate cells.

Authors:  Sumit Bhattacharyya; Leo Feferman; Xiaorui Han; Yilan Ouyang; Fuming Zhang; Robert J Linhardt; Joanne K Tobacman
Journal:  J Biol Chem       Date:  2018-05-24       Impact factor: 5.157

Review 2.  Potential for clinical radionuclide-based imaging and therapy of common cancers expressing EGFR-family receptors.

Authors:  Jörgen Carlsson
Journal:  Tumour Biol       Date:  2012-01-07

3.  Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.

Authors:  J Carlsson; L Shen; J Xiang; J Xu; Q Wei
Journal:  Oncol Lett       Date:  2012-10-25       Impact factor: 2.967

4.  Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.

Authors:  Sumit Isharwal; Michael Craig Miller; Jonathan I Epstein; Leslie A Mangold; Elizabeth Humphreys; Alan W Partin; Robert W Veltri
Journal:  Int J Cancer       Date:  2008-12-01       Impact factor: 7.396

5.  CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Authors:  Sreenivasa R Chinni; Hamilto Yamamoto; Zhong Dong; Aaron Sabbota; R Daniel Bonfil; Michael L Cher
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

Review 6.  Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery.

Authors:  Julia Y Ljubimova; Manabu Fujita; Alexander V Ljubimov; Vladimir P Torchilin; Keith L Black; Eggehard Holler
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

7.  miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer.

Authors:  Michael R Epis; Keith M Giles; Andrew Barker; Tulene S Kendrick; Peter J Leedman
Journal:  J Biol Chem       Date:  2009-07-07       Impact factor: 5.157

8.  Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.

Authors:  Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

9.  Genomic and epigenomic alterations in prostate cancer.

Authors:  Anna M Aschelter; Silvana Giacinti; Paola Caporello; Paolo Marchetti
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-06       Impact factor: 5.555

Review 10.  Persistent androgen receptor addiction in castration-resistant prostate cancer.

Authors:  Michael T Schweizer; Evan Y Yu
Journal:  J Hematol Oncol       Date:  2015-11-13       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.